KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?

Authors :: G. Speranza
Enriqueta Felip
Helge Bischoff
Ross Jennens
Martin Reck
J. Yang
Michael Boyer
S. Cheng
S. Gadgeel
Nir Peled
Emilio Esteban
Francesco Grossi
M.C. Garassino
M.C. Pietanza
Steven Francis Powell
Manuel Domine
Maximilian Hochmair
Rina Hui
D. Rodriguez Abreu
Edward B. Garon
Source :: Web of Science
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: 0301 basic medicine
Oncology
medicine.medical_specialty
business.industry
chemistry.chemical_element
Pembrolizumab
Hematology
Placebo
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Pemetrexed
chemistry
030220 oncology & carcinogenesis
Internal medicine
medicine
Platinum
business
medicine.drug

Full Text Access

Tools